The long-anticipated advances in therapeutic treatments to improve outcomes in both relapsing and progressive MS are coming closer to fruition. Although much of the evidence is still preclinical, the variety and scope of the ongoing research promises to provide new and novel options to manage this disease in the relatively near future.

Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/219/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/216)

Hosted on Acast. See acast.com/privacy for more information.